OncoMatch/Clinical Trials/NCT06469281
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Is NCT06469281 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Cemiplimab and Bevacizumab for epithelial ovarian cancer.
Treatment: Cemiplimab · Bevacizumab — This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2) major parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may include other medications given in combination with 27T51. Information collected from this study will help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors such as ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: MUC16 overexpression (CA125 ≥ 2 × ULN)
Serum cancer antigen (CA) 125 ≥ 2 × upper limit of normal (ULN) as assessed at the local lab by a 510(k) cleared test at screening
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cellular or gene therapy
Lab requirements
Blood counts
Absolute lymphocyte count (ALC) ≥ 100 cells/μL at time of leukapheresis; inadequate coagulation parameters as described in the protocol
Kidney function
as described in the protocol
Liver function
as described in the protocol
Cardiac function
as described in the protocol
Inadequate cardiovascular, renal and hepatic function, as described in the protocol; Absolute lymphocyte count (ALC) < 100 cells/μL at time of leukapheresis; inadequate coagulation parameters, as described in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- John Theurer Cancer Center Hackensack University Medical Center · Hackensack, New Jersey
- Roswell Park Cancer Institute · Buffalo, New York
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
- LDS Hospital · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify